The convergence of new technology platforms (including induced pluripotent stem cells, CRISPR-Cas9 gene editing, 3D biology, and advanced imaging) with other disciplines such as cheminformatics, machine learning, and artificial intelligence, have led to an exciting renaissance of phenotypic drug discovery.
This meeting will integrate academic and industry approaches to PDD, covering evolving advances in new PDD technologies and biological models, across various human disease areas. The program will address critical barriers in the field, including how to improve the physiological relevance of phenotypic models, identifying phenotypic targets and mechanisms of action. Attendees will learn new techniques and tools to advance their research, and the field.
Applications of Modern Computational Techniques to PDD
Phenotypical Approaches to Tackling Infectious Disease
Novel Chemistry to Enable PDD
Innovative Cell and Animal Models to Advance PDD
Systems Biology Approaches to Chemical Biology
Advances in Approaches to Understand Mechanism of Action
Featuring presentations by industry leaders including Genentech, Abbvie, Merck, Novartis and more!
Shannon Weiman earned her PhD in Biomedical Sciences from the University of California, San Diego, specializing in microbiology and immunology. Prior to joining the Keystone Symposia team, she worked as a freelance writer for leaders in academic, industry and government research, including Stanford University’s Biomedical Innovation Initiative, the University of Colorado’s Biofrontiers Program, UCSF, the FDA and the American Society for Microbiology.